- Home
- HNNA vs ABOS Comparison
HNNA vs ABOS Comparison
Compare HNNA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNNA
- ABOS
- Stock Information
- Founded
- HNNA 1989
- ABOS 1996
- Country
- HNNA United States
- ABOS United States
- Employees
- HNNA N/A
- ABOS N/A
- Industry
- HNNA Investment Managers
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- HNNA Finance
- ABOS Health Care
- Exchange
- HNNA Nasdaq
- ABOS Nasdaq
- Market Cap
- HNNA 82.4M
- ABOS 76.9M
- IPO Year
- HNNA N/A
- ABOS 2021
- Fundamental
- Price
- HNNA $10.99
- ABOS $1.08
- Analyst Decision
- HNNA
- ABOS Strong Buy
- Analyst Count
- HNNA 0
- ABOS 3
- Target Price
- HNNA N/A
- ABOS $7.33
- AVG Volume (30 Days)
- HNNA 23.5K
- ABOS 268.9K
- Earning Date
- HNNA 05-07-2025
- ABOS 05-13-2025
- Dividend Yield
- HNNA 5.00%
- ABOS N/A
- EPS Growth
- HNNA 75.66
- ABOS N/A
- EPS
- HNNA 1.12
- ABOS N/A
- Revenue
- HNNA $33,210,000.00
- ABOS N/A
- Revenue This Year
- HNNA N/A
- ABOS N/A
- Revenue Next Year
- HNNA N/A
- ABOS N/A
- P/E Ratio
- HNNA $9.24
- ABOS N/A
- Revenue Growth
- HNNA 38.27
- ABOS N/A
- 52 Week Low
- HNNA $6.60
- ABOS $0.86
- 52 Week High
- HNNA $13.88
- ABOS $3.92
- Technical
- Relative Strength Index (RSI)
- HNNA 60.98
- ABOS 48.99
- Support Level
- HNNA $9.46
- ABOS $0.95
- Resistance Level
- HNNA $10.78
- ABOS $1.13
- Average True Range (ATR)
- HNNA 0.73
- ABOS 0.13
- MACD
- HNNA 0.19
- ABOS 0.02
- Stochastic Oscillator
- HNNA 99.61
- ABOS 71.43
About HNNA Hennessy Advisors Inc.
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.